TAK-020 free base · Synonyms: TAK 020 · TAK020

TAK-020 is a highly selective covalent BTK inhibitor of both B cell receptor.

For research use only. Not for human or veterinary use.

Target Btk

Research area Inflammation/Immunology

Purity >98% Stock Inquire

Data Sheet SDS COA

TAK-020 structure

CAS No.: 1627603-21-7

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
10 mg	USD 490.00	BP-01909-10mg	In stock	Get quote
25 mg	USD 890.00	BP-01909-25mg	In stock	Get quote
50 mg	USD 1,390.00	BP-01909-50mg	In stock	Get quote
100 mg	USD 2,090.00	BP-01909-100mg	In stock	Get quote
250 mg	USD 3,190.00	BP-01909-250mg	In stock	Get quote
500 mg	Inquire	BP-01909-500mg	In stock	Inquire
1 g	Inquire	BP-01909-1g	Inquire	Inquire

Need another size or custom synthesis? Request a quote.

Description

TAK-020 is a highly selective covalent BTK inhibitor that inhibits both B cell receptor and fragment crystallizable receptor signaling

Identifiers

SMILES: O=C1NNC(C2=CC3=C(C(O[C@@H]4CN(C(C=C)=O)CC4)=N2)C=CC=C3)=N1
InChIKey: HIMUHMBGRATXMK-LBPRGKRZSA-N

Specifications

MW (average): 351.3593
Formula: C₁₈H₁₇N₅O₃
CAS No.: 1627603-21-7
Physical state: Solid
Color: White to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO 20.83 mg/mL

Documents

References

[1]. Sabat M, Dougan DR, Knight B, Lawson JD, Scorah N, Smith CR, Taylor ER, Vu P, Wyrick C, Wang H, Balakrishna D, Hixon M, Madakamutil L, McConn D. Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design. J Med Chem. 2021 Sep 9;64(17):12893-12902. doi: 10.1021/acs.jmedchem.1c01026. Epub 2021 Aug 27. PMID: 34448571.

[2]. Esfandiari E, Chen M, Smithson G, Blair D, Faessel H, Wagner J, Mclean L, Fedyk ER. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Multiple-Rising-Dose Study of the BTK Inhibitor TAK-020 in Healthy Subjects. Clin Transl Sci. 2021 May;14(3):820-828. doi: 10.1111/cts.12871. Epub 2021 Mar 2. PMID: 33650758; PMCID: PMC8212709.

Same target

Search Btk

Same research area

Search Inflammation/Immunology